Mizolastine
Trade name: zolistan
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2009 (NCT01928316)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Histamine H1 receptorANTAGONIST
Histamine H1 receptor antagonist
- Histamine H1 receptorBINDING AGENT
HRH1 binding agent
- Histamine H4 receptorBINDING AGENT
HRH4 binding agent
Chemistry & pharmacology
Loading structure…
SMILES
CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1- Mol. weight
- 432.5 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL94454 ↗
Also known as
- allphar brand of mizolastine
- galderma brand of mizolastine
- mistalin
- mistamine
- mistamine
- mizolastine
- mizolastine
- mizolastine
- mizolastine
- mizolastine
- mizolastine
- mizolastine
- mizolen
- mizollen
- mizollen
- mizollen
- mizollen
- novag brand of mizolastine
- sanofi synthelabo brand of mizolastine
- schwarz brand of mizolastine
- sl 85.0324
- sl 85.0324
- sl-85.0324
- sl-85.0324
- sl-85.0324
- sl-85.0324
- sl-85.0324
- zolim
- zolistan
- zolistan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01928316 | Phase 1 | Jun 1, 2009 | Johnson and Johnson |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2009 |
1 organizations
Page 1 / 1